BioSpace News Archive

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2022.

Anika Therapeutics, Inc. announced that on May 2, 2022, Anika granted non-statutory stock options covering an aggregate of 13,091 shares of common stock at a per share exercise price of $21.61.

Blue Water Vaccines Inc., announced its financial results for the first quarter ended March 31, 2022 and provided an update on recent business developments and progress.

Greenbrook TMS Inc., announced its first quarter 2022 operational and financial results.

On May 12, the US Food and Drug Administration (FDA) granted approval to oral edaravone (RADICAVA ORS) for the treatment of amyotrophic lateral sclerosis (ALS).

CureDuchenne announced the promotion of Lianna Orlando, PhD, to Vice President of Research and the addition of Bradley Hodges, PhD as Partner of CureDuchenne Ventures.

Promore Pharma AB publishes its interim report for the first quarter 2022 on 17 May 2022.

Qualigen Therapeutics, Inc. announces its financial results for the first quarter ended March 31, 2022, and provides an update on its diagnostics business, therapeutics pipeline, and other corporate developments.

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the full U.S. commercial launch of its UroLift ® 2 System and UroLift ATC ® System, and that it will update the urology community through multiple in-booth presentations at the 2022 American Urological Association (AUA) annual meeting.

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the first quarter ended March 31, 2022 and provided a corporate update.